These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 18690383

  • 1. Abiotrophia spp. and Staphylococcus epidermidis endocarditis treated with daptomycin.
    Bishburg E, Ghuman D, Cohen A, Chan T, Nalmas S.
    ScientificWorldJournal; 2008 Aug 08; 8():793-5. PubMed ID: 18690383
    [Abstract] [Full Text] [Related]

  • 2. Daptomycin for methicillin-resistant Staphylococcus epidermidis native-valve endocarditis: a case report.
    Duah M.
    Ann Clin Microbiol Antimicrob; 2010 Feb 18; 9():9. PubMed ID: 20167084
    [Abstract] [Full Text] [Related]

  • 3. Successful Use of High-dose Daptomycin in a Child With Staphylococcus aureus Endocarditis.
    Prabhudesai S, Kanjani A, Nambi PS, Gnanasambandam S, Ramachandran B.
    Pediatr Infect Dis J; 2016 May 18; 35(5):517-8. PubMed ID: 27074655
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.
    Sakoulas G, Eliopoulos GM, Alder J, Eliopoulos CT.
    Antimicrob Agents Chemother; 2003 May 18; 47(5):1714-8. PubMed ID: 12709345
    [Abstract] [Full Text] [Related]

  • 5. Successful treatment of Corynebacterium striatum endocarditis with daptomycin plus rifampin.
    Shah M, Murillo JL.
    Ann Pharmacother; 2005 Oct 18; 39(10):1741-4. PubMed ID: 16144879
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Indications for daptomycin use in endocarditis and pacemaker lead infection and outcomes in Leeds, UK.
    Sandoe J, Baig W.
    Future Cardiol; 2012 Jul 18; 8(4):547-54. PubMed ID: 22871194
    [Abstract] [Full Text] [Related]

  • 9. Rapidly destructive Staphylococcus epidermidis endocarditis.
    Zinkernagel AS, Speck RF, Ruef C, Zingg W, Berger-Bachi B, Springer B.
    Infection; 2005 Jun 18; 33(3):148-50. PubMed ID: 15940416
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations.
    Rose WE, Leonard SN, Rybak MJ.
    Antimicrob Agents Chemother; 2008 Sep 18; 52(9):3061-7. PubMed ID: 18591272
    [Abstract] [Full Text] [Related]

  • 12. Association between daptomycin susceptibility and teicoplanin resistance in Staphylococcus epidermidis.
    Watanabe S, Kawakami Y, Kimura H, Murakami S, Miyamoto H, Takatori S, Suemori K, Tanaka M, Tanaka A, Tanaka K, Tauchi H, Maki J, Araki H, Yamaguchi T.
    Sci Rep; 2019 Dec 06; 9(1):18533. PubMed ID: 31811214
    [Abstract] [Full Text] [Related]

  • 13. Ciprofloxacin therapy of experimental endocarditis caused by methicillin-resistant Staphylococcus epidermidis.
    Rouse MS, Wilcox RM, Henry NK, Steckelberg JM, Wilson WR.
    Antimicrob Agents Chemother; 1990 Feb 06; 34(2):273-6. PubMed ID: 2327776
    [Abstract] [Full Text] [Related]

  • 14. Combination therapy with daptomycin, vancomycin, and rifampin for recurrent, severe bone and prosthetic joint infections involving methicillin-resistant Staphylococcus aureus.
    Antony SJ.
    Scand J Infect Dis; 2006 Feb 06; 38(4):293-5. PubMed ID: 16718933
    [Abstract] [Full Text] [Related]

  • 15. High-dose daptomycin for the treatment of endocarditis caused by Staphylococcus aureus with intermediate susceptibility to glycopeptides.
    Lichterfeld M, Ferraro MJ, Davis BT.
    Int J Antimicrob Agents; 2010 Jan 06; 35(1):96. PubMed ID: 19896341
    [No Abstract] [Full Text] [Related]

  • 16. Staphylococcus epidermidis endocarditis treated with RP 59500 (quinapristin/dalfopristin).
    Larkin J, Busciglio L, Fontanet H, Gamouras G.
    Clin Infect Dis; 1998 May 06; 26(5):1239-40. PubMed ID: 9597268
    [No Abstract] [Full Text] [Related]

  • 17. [Severe daptomycin-induced myopathy].
    Ferrera C, Vilacosta I, Vivas D, Olmos C.
    Med Clin (Barc); 2012 Jun 30; 139(3):138-9. PubMed ID: 22285497
    [No Abstract] [Full Text] [Related]

  • 18. Role of tolerance in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis with vancomycin, teicoplanin, and daptomycin.
    Voorn GP, Kuyvenhoven J, Goessens WH, Schmal-Bauer WC, Broeders PH, Thompson J, Michel MF.
    Antimicrob Agents Chemother; 1994 Mar 30; 38(3):487-93. PubMed ID: 8203842
    [Abstract] [Full Text] [Related]

  • 19. Successful treatment of daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus bacteremia with the addition of rifampin to daptomycin.
    Ahmad NM, Rojtman AD.
    Ann Pharmacother; 2010 May 30; 44(5):918-21. PubMed ID: 20354160
    [Abstract] [Full Text] [Related]

  • 20. Staphylococcus epidermidis endocarditis and mitral valve prolapse.
    Ferreira AC, Cohen J.
    J Infect; 1988 Jan 30; 16(1):73-6. PubMed ID: 3367058
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.